QP002

QP002 is a pharmaceutical drug developed by Nanjing Qingpu Biotechnology. It is being investigated as a topical gel formulation for postoperative analgesia, specifically to manage pain following orthopedic surgeries such as unilateral total hip replacement and hallux valgus correction (bunion surgery). The drug is currently in Phase 2 clinical trials, where its efficacy, safety, and pharmacokinetic characteristics are being evaluated. The precise molecular target or mechanism of action has not been disclosed in public sources. Its development focuses on the nervous system therapeutic area, particularly for acute pain management after surgical procedures[1][9].